Share

3rd Annual Brain Metastases Research and Emerging Therapy Conference

We are pleased to welcome you to Marseille for the third Annual Brain Metastases Research and Emerging Therapy Conference. Last year’s successful edition has prompted us to once again organize this conference. Over the past several months, the EORTC has launched the development of a Brain Metastasis platform, created in August 2012, in order to optimally develop and conduct projects focusing on brain metastases.

This research platform brings together the multidisciplinary approach that is needed to develop brain metastases projects across several tumor types and disciplines such as breast cancer, lung cancer, melanoma, imaging, pathobiology and radiation oncology. It is expected that this cross-sectional platform stimulates innovative and insightful research in a collaborative environment in order to improve the standard of care and methodology of clinical research.

Together, the EORTC, GRPCMac and Canceropole PACA have decided to jointly organize the “Annual Brain Metastases Research and Emerging Therapy Conference” which will be held under the auspices of the EORTC. The organizing committee hopes that this meeting will provide an exceptional opportunity for you to share your collective expertise ranging from basic science to new treatments in order to facilitate ongoing studies and lay the foundation for future collaborative projects.

On behalf of the Organizing Committee.

Back to news list

Related News

  • Professor Benjamin Besse becomes President of EORTC

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Interview of ROSC Chair, Joost Vaerhoeff